Tango Therapeutics is advancing in cancer treatment with Phase 1/2 clinical trials for TNG908 and TNG462, targeting MTAP-deleted tumors. Tango's stock soared by over 100% following Mirati's ...
Tango Therapeutics Inc. (TNGX) stock reached a 52-week high, trading at $11.21. According to InvestingPro data, the current price of $11.39 continues to push beyond this milestone, with the stock now ...
Tango Therapeutics Inc (TNGX) stock has reached a new 52-week high, climbing to 12.67 USD. This milestone reflects a significant upward trend over the past year, with the stock delivering a remarkable ...
Bank of New York Mellon Corp lessened its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) by 7.8% during the 4th quarter, HoldingsChannel reports. The fund owned 103,020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results